The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study*

References

• National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes Statistics. Available at: http://diabetes.niddk.nih.gov/ dm/pubs/statistics/index.htm#7. [Accessed 26 Jan 2004]
   Google Scholar
• Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993;16:642–52
   PubMed Web of Science ®Google Scholar
• Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995;18:258–68
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Andrew H, Neil W, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR (on behalf of the U.K. Prospective Diabetes Study Group). Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321: 405–12
   Google Scholar
• United States Renal Data System (USRDS). 2003 USRDS Annual Data Report. Available at: http://www.usrds.org/ atlas.htm. [Accessed 20 Oct 2003]
   Google Scholar
• de Grauw WJ, van de Lisdonk EH, Behr RR, van Gerwen WH, van den Hoogen HJ, van Weel C. The impact of type 2 diabetes mellitus on daily functioning. Fam Pract 1999;16:133–9
   PubMed Web of Science ®Google Scholar
• Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group. Diabetes Care 1999;22:1125–36
   PubMed Web of Science ®Google Scholar
• Goddijn PP, Bilo HJ, Feskens EJ, Groeniert KH, van der Zee KI, Meyboom-de Jong B. Longitudinal study on glycaemic control and quality of life in patients with Type 2 diabetes mellitus referred for intensified control. Diabet Med 1999;16:23–30
   Google Scholar
• Van der Does FE, De Neeling JN, Snoek FJ, Kostense PJ, Grootenhuis PA, Bouter LM, Heine RJ. Symptoms and well-being in relation to glycemic control in type II diabetes. Diabetes Care 1996;19:204–10
   PubMed Web of Science ®Google Scholar
• United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998;128:165–75
   PubMed Web of Science ®Google Scholar
• The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1998;329:977–86
   Google Scholar
• Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287: 2563–9
   Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854–65
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837–53
   PubMed Web of Science ®Google Scholar
• Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care 1999;22\(Suppl. 2):B109–13
   Google Scholar
• Levien TL, Baker DE, White JR Jr, Campbell RK. Insulin glargine: a new basal insulin. Ann Pharmacother 2002;36: 1019–27
   PubMed Web of Science ®Google Scholar
• Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000;23:1666–71
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Park G, Zimmerman J. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care 2000;23: 1137–42
   Google Scholar
• Murphy NP, Keane SM, Ong KK, Ford-Adams M, Edge JA, Acerini CL, Dunger DB. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003;26: 799–804
   Google Scholar
• Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM. Development of a type 2 diabetes symptom checklist: a measure of symptom severity. Diabet Med 1994;11:253–61
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83
   Google Scholar
• Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K. Pediatric Study Group of Insulin Glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes. Diabetes Care 2001;24:2005–6
   Google Scholar
• Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23: 1130–6
   Google Scholar
• Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631–6
   PubMed Web of Science ®Google Scholar